This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, K. Articles by Harris, A. L. Search for Related Content PubMed PubMed Citation Articles by Smith, K. Articles by Harris, A. L.

Characterization and Quantitation of the Epidermal Growth Factor Receptor in Invasive and Superficial Bladder Tumors¹

Cancer Research Unit, Department of Clinical Oncology [K. S., J. A. F., A. L. H.], and University Department of Surgery [D. E. N., R. R. H.], University of Newcastle upon Tyne and Department of Urology, Freeman Hospital, Newcastle upon Tyne, England

Epidermal growth factor receptors (EGFr) have been measured on primary human bladder tumor membranes by ¹²⁵I-EGF ligand binding. High affinity receptors were detected on both superficial (K_d 0.2–1.45 nM; mean, 0.86 nM; median, 0.88 nM) and invasive tumors (K_d 0.19–2.38 nM; mean, 0.9 nM, median, 0.79 nM). There was one class of binding sites and EGFr concentration was quantified by competitive binding and Scatchard analysis. The EGFr was further characterized and shown to be cleaved at the major autophosphorylation site by a calcium-activated mechanism. Thus the EGFr from primary bladder tumors exhibits similar biochemical characteristics to those in established cell lines. Tumors classified as invasive on the basis of muscle invasion had higher EGFr levels [EGF binding, 99 ± 252 (SD) fmol/mg protein; median, 21; n = 24] than superficial tumors (12 ± 12 fmol/mg protein; median, 11; n = 23) or normal bladder mucosa (9 ± 12 fmol/mg protein; median, 6; n = 6) (P = 0.05). When the two largest subgroups of superficial and invasive tumors were compared (15 pTa, 16 T3), the invasive tumors had significantly higher EGFr levels (P < 0.05). EGFr may therefore be involved in mechanisms of tumor progression. EGFr may be a target for selective therapy with EGF-linked drugs in a subset of invasive bladder cancers.

¹ Supported by the North of England Cancer Company.

Received 6/27/88. Revised 1/ 5/89. Revised 5/15/89. Accepted 7/21/89.

This article has been cited by other articles:

				R. A. Mason, E. V. Morlock, M. R. Karagas, K. T. Kelsey, C. J. Marsit, A. R. Schned, and A. S. Andrew EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis Carcinogenesis, July 1, 2009; 30(7): 1155 - 1160. [Abstract] [Full Text] [PDF]

				J. Kim, R. M. Adam, and M. R. Freeman Trafficking of Nuclear Heparin-Binding Epidermal Growth Factor-like Growth Factor into an Epidermal Growth Factor Receptor-Dependent Autocrine Loop in Response to Oxidative Stress Cancer Res., September 15, 2005; 65(18): 8242 - 8249. [Abstract] [Full Text] [PDF]

				T. T. Junttila, M. Laato, T. Vahlberg, K.-O. Soderstrom, T. Visakorpi, J. Isola, and K. Elenius Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients Clin. Cancer Res., November 1, 2003; 9(14): 5346 - 5357. [Abstract] [Full Text] [PDF]

				J. J. Gildea, M. J. Seraj, G. Oxford, M. A. Harding, G. M. Hampton, C. A. Moskaluk, H. F. Frierson, M. R. Conaway, and D. Theodorescu RhoGDI2 Is an Invasion and Metastasis Suppressor Gene in Human Cancer Cancer Res., November 15, 2002; 62(22): 6418 - 6423. [Abstract] [Full Text] [PDF]

				A. E. Marjou, A. Delouvee, J. P. Thiery, and F. Radvanyi Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression Carcinogenesis, December 1, 2000; 21(12): 2211 - 2218. [Abstract] [Full Text] [PDF]

				K. Inoue, J. W. Slaton, P. Perrotte, D. W. Davis, C. J. Bruns, D. J. Hicklin, D. J. McConkey, P. Sweeney, R. Radinsky, and C. P. N. Dinney Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma Clin. Cancer Res., December 1, 2000; 6(12): 4874 - 4884. [Abstract] [Full Text]

				L Zhang, M. Rees, and R Bicknell The isolation and long-term culture of normal human endometrial epithelium and stroma. Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progesterone challenges J. Cell Sci., January 1, 1995; 108(1): 323 - 331. [Abstract] [PDF]